FDA’s Interchangeability Improvements Impress Industry
Executive Summary
Using comparator biologics not licensed in the US is foreseen in final FDA interchangeability guidance, shifting the agency’s previous stance on biosimilars.
You may also be interested in...
Biosimilar Interchangeability: A Blessing Or A Curse?
Biosimilar interchangeability is a hot topic in the US, with the first FDA decision on a formal interchangeability designation expected this month. But across the industry, views differ dramatically on the desirability and likely impact of this additional standard to biosimilarity.
Biosimilar Interchangeability: A Blessing Or A Curse?
Biosimilar interchangeability is a hot topic in the US, with the first FDA decision on a formal interchangeability designation expected this month. But across the industry, views differ dramatically on the desirability and likely impact of this additional standard to biosimilarity.
Nichi-Iko Looks To File For Interchangeable Infliximab In US Next Year
With a US filing for interchangeable infliximab scheduled for next year, Nichi-Iko is lining up a launch of etanercept in Japan as it seeks alliances to broaden its biosimilars pipeline.